研究者業績

堀江 久永

ホリエ ヒサナガ  (Hisanaga Horie)

基本情報

所属
自治医科大学 医学部外科学講座消化器一般移植外科部門 / 附属病院中央手術部 教授

J-GLOBAL ID
200901023616258751
researchmap会員ID
5000100066

研究キーワード

 1

論文

 703
  • Hideyo Miyato, Shin Saito, Hideyuki Ohzawa, Hironori Yamaguchi, Hiroshi Kawahira, Hisanaga Horie, Yoshinori Hosoya, Toshiki Mimura, Naohiro Sata, Joji Kitayama
    Experimental cell research 115028-115028 2026年5月5日  
    BACKGROUND: Recent studies reveal that during trogocytosis plasma membranes are frequently transferred upon cell-to-cell contact, and that this phenomenon plays an important role in the modulation of anti-tumor immune response. However, the accompanying physiological roles in the tumor microenvironment are poorly understood. METHODS & RESULTS: Human gastric cancer cell line OCUM-1 was co-cultured with T cells whose plasma membrane was stained with PKH26. Flow-cytometric analysis revealed that OCUM-1 was positive for PKH26 at one hour and the positive rate increased over time. The acquisition of PKH26 was dependent on cell-to-cell contact and suppressed when T cells were fixed. OCUM-1 came to express various immunological synapse molecules after 10 hours of co-culture (positive rate, CD45:73.6±7.9%, CD3: 35.5±10.1%, CD4: 15.3±14.7%, CD8: 7.7±2.4%, CD11a: 8.1±4.3%, CD11b: 3.4±1.9%). We focused on CD11a which belongs to β2 integrins and aids immune cell adherence to endothelial cells. After co-culture with activated T cells (LAK), the expression level of CD11a on OCUM-1 was accelerated (with T cells: 19.1±13.4%, with LAK: 75.2±11.8%) and the adhesion rate on endothelial cells increased in a CD11a dependent manner (adhesion rate, single-culture: 2.0±0.64%, co-culture: 6.3±2.0%, co-culture (pre-treat with CD11a antibody): 2.3±1.4%, n=10, single-culture vs co-culture, p<0.0001; co-culture vs pre-treat with CD11a antibody, p<0.0001). CONCLUSION: These results suggest that acquisition of CD11a from T cells by trogocytosis enables cancer cells to increase adhesive properties towards endothelial cells, which may result in intravenous metastasis promotion.
  • Masanobu Taguchi, Hideki Sasanuma, Kentaro Shimodaira, Yuki Kimura, Yuichi Aoki, Yoshiyuki Meguro, Naoya Kasahawa, Kazue Morishima, Hideyo Miyato, Hideyuki Ohzawa, Atsushi Miki, Yuji Kaneda, Kazuhiro Endo, Masaru Koizumi, Yasunaru Sakuma, Hiroharu Yamashita, Hisanaga Horie, Naohiro Sata, Hironori Yamaguchi
    Surgical oncology 65 102386-102386 2026年2月18日  
    BACKGROUND: Neoadjuvant therapy has been increasingly adopted for resectable pancreatic ductal adenocarcinoma (PDAC) in Japan following the Prep-02/JSAP-05 trial. However, real-world evidence regarding effectiveness and underlying pathological mechanisms remains limited. This retrospective study evaluated neoadjuvant chemotherapy with gemcitabine plus S-1 (NAC-GS) impacts on resectable PDAC patient oncological and pathological outcomes. METHODS: Consecutive resectable PDAC patients treated with NAC-GS (n = 60) or upfront surgery (UFS) (n = 101) between 2013 and 2023 were retrospectively analyzed (total diagnosed during the study period, n = 186). An intention-to-treat principle assessed overall survival (OS) and recurrence-free survival (RFS). Propensity score matching using six baseline variables (1:1) minimized selection bias. RESULTS: Fifty-four patients were included in each group. The NAC-GS group demonstrated significantly longer OS than the UFS group (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.25-0.90; P = 0.023). Among resected cases, NAC-GS was associated with improved OS (HR, 0.42; 95% CI, 0.20-0.90; P = 0.026). Pathologically, the NAC-GS group showed significantly lower lymph node stage and less lymphatic invasion. Pathological complete response was observed in 4.0% of NAC-GS patients. DISCUSSION: Neoadjuvant chemotherapy with GS was associated with prolonged survival in resectable PDAC, potentially through lymphatic spread suppression. Pathological complete response was rare but may represent a clinically meaningful benefit of neoadjuvant treatment in selected patients.
  • Yuichi Aoki, Atsushi Miki, Yasunaru Sakuma, Jun Watanabe, Takehiro Kagaya, Makiko Tahara, Takumi Teratani, Kazuhiro Endo, Hideki Sasanuma, Wataru Nishimura, Hisanaga Horie, Joji Kitayama, Naohiro Sata, Hironori Yamaguchi
    PloS one 20(6) e0324719 2025年  
    BACKGROUND: This study aimed to elucidate the clinical impact of osteopenia on the recurrence of colon cancer liver metastases. METHODS: Patients with colon cancer liver metastases (N = 186) undergoing hepatectomy at Jichi Medical University Hospital between March 2006 and March 2020 were examined retrospectively. Computed tomography (CT) scans on the 11th vertebra within 3 months of surgery assessed bone mineral density (BMD). Age-adjusted BMD determined osteopenia presence. Kaplan-Meier method with a log-rank test estimated survival. Factors associated with survival were assessed using Cox's proportional hazards model after adjustment for confounders. RESULTS: Patients with osteopenia had shorter overall (p = 0.0001; 5-year overall survival, 51.8% vs 81.8%) and recurrence-free survival (p = 0.0008, 5-year recurrence-free survival: 26.3% vs 51.5%) than BMD-normal patients. In multivariable analysis, the risk factor for overall survival was osteopenia (Hazard ratio (HR) 3.79, 95% confidence interval (CI) 2.09-6.87, p = 0.001). Risk factors for recurrence were chemotherapy (HR 1.92, 95%CI 1.12-3.30, p = 0.002), tumor number (HR 1.51, 95%CI 1.02-2.27, p = 0.04), and osteopenia (HR 2.18, 95%CI 1.46-3.24 p = 0.001). Patients with osteopenia are more likely to develop lung metastases, and BMD-value reduction associated with KRAS mutation. CONCLUSION: Osteopenia may have prognostic significance in patients with liver metastases colorectal cancer.
  • 佐田 友藍, 伊藤 豪, 向山 順子, 門間 聡子, 柵山 尚紀, 愛甲 丞, 鯉沼 広治, 味村 俊樹, 堀江 久永, 北山 丈二, 山口 博紀, 佐田 尚宏, 志田 大
    日本臨床外科学会雑誌 85(増刊) S487-S487 2024年10月  

MISC

 327

共同研究・競争的資金等の研究課題

 9